ENA21 Poster 005

Establishment and Characterization of a Panel of Advanced Prostate Cancer Patient-Derived Xenograft (PDX) Models for Cancer Therapeutic Evaluation

Jessie J.J. Wang, Leilei Chen, Xueying Yang, Likun Zhang, Wubin Qian, Henry Q.X. Li He1, Keyi Zhu1, Ruilin Sun², Lei Zheng1, Annie X. An1, Henry Q.X. Li^1
1Crown Bioscience Inc., 16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA 92127, USA; ²Shanghai Model Organisms Center, Inc., 3577 Jinke Rd, Shanghai, 201203 China

Prostate cancer is one of the most frequently diagnosed solid malignancies and is accountable for the second highest cancer-related deaths in males worldwide. Despite the success of targeting the androgen receptor signaling pathway with androgen deprivation therapy (ADT) and androgen receptor blockage (ARB), relapse and resistance to treatment leads to castration resistant prostate cancer (CRPC) or metastatic CRPC (mCRPC), resulting in poor clinical prognosis and therapeutic outcome. Prostate cancer is a highly heterogeneous disease, with different molecular pathways playing a role in the advanced disease, such as androgen receptor mutations, DNA repair gene deletions, P53 aberrations, RB1 function loss, as well as gene rearrangements, like TMPRSS2-ERG2.

View our poster to understand why preclinical models representing CRPC heterogeneity and clinically relevant responses to standard of care treatments are needed to better understand the biology and mechanisms of this malignancy.

Download this Poster to Discover:

• A series of mCRPC prostate PDX models derived from differentmetastatic sites
  
  
• How the prostate PDX models were characterized using pathology techniques and prostate specific markers using IHC
  
  
• How these mCRPC prostate PDX models show slow growth under castration conditions, and had different responses to docetaxel and enzalutamide

Download the Poster Now!